173 related articles for article (PubMed ID: 26462017)
21. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Kim SL; La MT; Shin MW; Kim SW; Kim HK
Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
[TBL] [Abstract][Full Text] [Related]
22. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
[TBL] [Abstract][Full Text] [Related]
23. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
[TBL] [Abstract][Full Text] [Related]
24. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
26. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
27. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
[TBL] [Abstract][Full Text] [Related]
28. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
29. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis.
Zhang N; Li X; Wu CW; Dong Y; Cai M; Mok MT; Wang H; Chen J; Ng SS; Chen M; Sung JJ; Yu J
Oncogene; 2013 Oct; 32(42):5078-88. PubMed ID: 23208495
[TBL] [Abstract][Full Text] [Related]
30. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
31. Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model.
Tang FY; Pai MH; Chiang EP
J Nutr Biochem; 2012 Oct; 23(10):1302-13. PubMed ID: 22221675
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
[TBL] [Abstract][Full Text] [Related]
33. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
34. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Götze S; Coersmeyer M; Müller O; Sievers S
Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
37. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin.
Wang LT; Liou JP; Li YH; Liu YM; Pan SL; Teng CM
Oncotarget; 2014 Jul; 5(14):5651-62. PubMed ID: 25015091
[TBL] [Abstract][Full Text] [Related]
38. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
39. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
40. A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer.
Jagadish N; Parashar D; Gupta N; Agarwal S; Purohit S; Kumar V; Sharma A; Fatima R; Topno AP; Shaha C; Suri A
J Exp Clin Cancer Res; 2015 Nov; 34():142. PubMed ID: 26590805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
